Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer …
LJ Swinnen, A O'Neill, PH Imus, S Gujar, D Schiff… - …, 2017 - pmc.ncbi.nlm.nih.gov
Background Therapy of primary CNS lymphoma (PCNSL) has focused on multi-agent
chemotherapy designed to cross the blood brain barrier. Rituximab has demonstrated
activity in PCNSL. E1F05 is an ECOG-ACRIN multicenter phase 2 prospective trial of
rituximab with high-dose methotrexate (HD-MTX)-based chemotherapy similar to the RTOG
93-10 regimen, omitting radiotherapy. Methods Immunocompetent patients with newly
diagnosed PCNSL received HD-MTX 3.5 g/m2 with vincristine every two weeks for 5 doses; …
chemotherapy designed to cross the blood brain barrier. Rituximab has demonstrated
activity in PCNSL. E1F05 is an ECOG-ACRIN multicenter phase 2 prospective trial of
rituximab with high-dose methotrexate (HD-MTX)-based chemotherapy similar to the RTOG
93-10 regimen, omitting radiotherapy. Methods Immunocompetent patients with newly
diagnosed PCNSL received HD-MTX 3.5 g/m2 with vincristine every two weeks for 5 doses; …
[HTML][HTML] Phase II Study of Rituximab Given in Conjunction with Standard Chemotherapy in Primary Central Nervous System Lymphoma (PCNSL)[E1F05]
LJ Swinnen, A O'Neill, PH Imus, S Gujar, D Schiff… - Blood, 2015 - Elsevier
Introduction Treatment of PCNSL has focused on multi-agent chemotherapy designed to
cross the blood brain barrier (BBB); radiation therapy (RT) has a high response rate, but
responses tend to be transient and associated with cognitive toxicity. The addition of
rituximab has improved treatment outcomes for virtually all CD20-positive B-cell
malignancies. Although rituximab is not believed to cross the BBB, enhancement on MRI
corresponds with areas of BBB breakdown that could allow penetration of the antibody. Here …
cross the blood brain barrier (BBB); radiation therapy (RT) has a high response rate, but
responses tend to be transient and associated with cognitive toxicity. The addition of
rituximab has improved treatment outcomes for virtually all CD20-positive B-cell
malignancies. Although rituximab is not believed to cross the BBB, enhancement on MRI
corresponds with areas of BBB breakdown that could allow penetration of the antibody. Here …
以上显示的是最相近的搜索结果。 查看全部搜索结果